Spyre Therapeutics (SYRE) total debt
Only 1 fiscal year of total debt is on record here for Spyre Therapeutics (SYRE); a history needs at least 3. Figures as of 18 Nov 2026, 06:21 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total debt, fiscal 2022
- $4.63M
- Fiscal years on record
- 12022–2022
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Not enough data
A history of total debt needs at least 3 fiscal years; one is on record here for Spyre Therapeutics. Nothing is estimated to fill the gap. What is on record is in the table below.
Spyre Therapeutics total debt, year by year
| Fiscal year | Total debt | Change | Year ended | Debt ÷ equity |
|---|---|---|---|---|
| 2022 | $4.63M | — | 0.1× |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
How to read it
Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.
Total debt at health care companies of similar size
| Company | Total debt | Fiscal year |
|---|---|---|
| Vaxcyte PCVX | $117.48M | 2025 |
| Bio-Rad Laboratories BIO | $1.39B | 2025 |
| Molina Healthcare MOH | $3.95B | 2025 |
| Spyre Therapeutics SYRE | $4.63M | 2022 |
| Qiagen QGEN | $1.81B | 2025 |
| Insulet PODD | $949.20M | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Spyre Therapeutics, figure by figure
- Spyre Therapeutics market cap
- Spyre Therapeutics revenue
- Spyre Therapeutics earnings
- Spyre Therapeutics earnings per share (EPS)
- Spyre Therapeutics P/E ratio
- Spyre Therapeutics P/S ratio
- Spyre Therapeutics P/B ratio
- Spyre Therapeutics free cash flow
- Spyre Therapeutics operating margin
- Spyre Therapeutics dividend
- Spyre Therapeutics shares outstanding
- Spyre Therapeutics cash on hand
- Spyre Therapeutics total assets
- Spyre Therapeutics return on equity (ROE)
- Spyre Therapeutics return on invested capital (ROIC)
Spyre Therapeutics (SYRE) overview: price, valuation and scorecardAll health care companies by market value
Spyre Therapeutics total debt: questions and answers
How is Spyre Therapeutics's total debt calculated?
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
Fiscal years are named for the calendar year they end in.
Learn: total debt
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Spyre Therapeutics (SYRE) total debt”, data as of 18 November 2026. https://funkfolio.com/stock/SYRE/total-debt
Underlying data: the company's filings with the SEC and Yahoo Finance.